Fig. 6.

Clinical associations of disease progression with hyperoxia exposure responses in a wide range of lung disease models were reversed in the Cyp1b1-null hyperoxia mitigation signature. Publicly available transcriptomics data from blood or lung tissues were used to perform clinical associations between hyperoxia signatures or hyperoxia mitigation signatures (summed z-scores) and disease progression. Data sets used were (A) Bronchopulmonary dysplasia (BPD) blood transcriptomics from newborns at d14 or d28 (GSE32472), (B) ARDS patient blood samples at d0 and d7 (GSE32707), (C) adenocarcinoma (LUAD) or squamous (LUSC) lung tumor samples from TCGA, and (D) Idiopathic pulmonary fibrosis (IPF) transcriptomics from blood (GSE93606) or lung tissues (GSE53845, GSE35145, GSE24206, and GSE110147). E. Detailed scatterplots from panel A (black boxes) show the association of hyperoxia exposure signatures in Cyp1a1-null, Cyp1a2-null, or Cyp1b1-null mice or the hyperoxia response mitigation signature of Cyp1b1-null mice with severity of BPD at d28. Associations were evaluated using the parametric Pearson correlation, with the Pearson correlation coefficient (r) and p-values indicated.